Summary of characteristics of 267 patients at diagnosis
Characteristics . | Number/value . | % . | Range . |
---|---|---|---|
Age, median, years | 63.0 | 29-94 | |
Sex | |||
Female | 125 | 47 | |
Male | 142 | 53 | |
Clinical subtype | |||
Chronic type | 149 | 56 | |
Smoldering type | 118 | 44 | |
Admitted to | |||
Hematology Department | 184 | 69 | |
Dermatology Department | 83 | 31 | |
Neutrophil count, median, ×109/L | 4.1 | 0.0-36.6 | |
Lymphocyte count, median, ×109/L | 4527 | 480-80 567.5 | |
Abnormal lymphocyte count, median, ×109/L | 1554 | 0.0-78 826 | |
Hemoglobin level, median, g/dL | 13.6 | 4.2-17.7 | |
Platelet count, median, ×109/L | 220 | 63-560 | |
Serum total protein, median, g/dL | 7.1 | 4.8-8.9 | |
Serum albumin, median, g/dL | 4.2 | 2.3-5.4 | |
BUN, median, mg/dL | 13.4 | 3.5-70.0 | |
LDH, median, IU/L | 246 | 122-926 | |
LDH > ULN, % | 134 | 50 | |
Soluble IL-2R, median, U/mL | 2796 | 192-162 000 | |
Increased CRP present | 83 | 31 | |
Stage | |||
I-II | 29 | 11 | |
III-IV | 238 | 89 | |
ECOG performance status | |||
0-1 | 248 | 93 | |
2-4 | 19 | 7 | |
B symptoms present | 26 | 10 | |
Number of lymph node lesions, median, range | 0 | 0-11 | |
Number of extranodal sites, median, range | 1 | 0-4 | |
Total number of involved lymph nodes and extranodal lesions, median, range | 4 | 0-13 | |
Bone marrow involvement present | 39 | 15 | |
Liver involvement present | 4 | 2 | |
Spleen involvement present | 13 | 5 | |
Skin lesions present | 162 | 61 | |
Lung involvement present | 12 | 4 |
Characteristics . | Number/value . | % . | Range . |
---|---|---|---|
Age, median, years | 63.0 | 29-94 | |
Sex | |||
Female | 125 | 47 | |
Male | 142 | 53 | |
Clinical subtype | |||
Chronic type | 149 | 56 | |
Smoldering type | 118 | 44 | |
Admitted to | |||
Hematology Department | 184 | 69 | |
Dermatology Department | 83 | 31 | |
Neutrophil count, median, ×109/L | 4.1 | 0.0-36.6 | |
Lymphocyte count, median, ×109/L | 4527 | 480-80 567.5 | |
Abnormal lymphocyte count, median, ×109/L | 1554 | 0.0-78 826 | |
Hemoglobin level, median, g/dL | 13.6 | 4.2-17.7 | |
Platelet count, median, ×109/L | 220 | 63-560 | |
Serum total protein, median, g/dL | 7.1 | 4.8-8.9 | |
Serum albumin, median, g/dL | 4.2 | 2.3-5.4 | |
BUN, median, mg/dL | 13.4 | 3.5-70.0 | |
LDH, median, IU/L | 246 | 122-926 | |
LDH > ULN, % | 134 | 50 | |
Soluble IL-2R, median, U/mL | 2796 | 192-162 000 | |
Increased CRP present | 83 | 31 | |
Stage | |||
I-II | 29 | 11 | |
III-IV | 238 | 89 | |
ECOG performance status | |||
0-1 | 248 | 93 | |
2-4 | 19 | 7 | |
B symptoms present | 26 | 10 | |
Number of lymph node lesions, median, range | 0 | 0-11 | |
Number of extranodal sites, median, range | 1 | 0-4 | |
Total number of involved lymph nodes and extranodal lesions, median, range | 4 | 0-13 | |
Bone marrow involvement present | 39 | 15 | |
Liver involvement present | 4 | 2 | |
Spleen involvement present | 13 | 5 | |
Skin lesions present | 162 | 61 | |
Lung involvement present | 12 | 4 |
BUN, blood urea nitrogen; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; IL-2R, interleukin-2 receptor; ULN, upper limit of normal.
The sIL-2R level by picogram per milliliter may be converted to units per milliliter, using the formula: value (pg/mL) × 0.113.